CD274 and breast carcinoma: Goel et al. first reported that abemaciclib plus anti-PD-L1 induced durable responses in preclinical models of HR+ breast cancer and mice deemed tumor free were protected from subsequent tumors when re-challenged with tumors, suggesting sustained immune memory (170).